NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , announced today that Michael S. Weiss, Chairman and Chief Executive Officer, will present an overview of the Company and upcoming milestones at the C.E. Unterberg, Towbin Life Sciences Conference in New York City. Mr. Weiss’ presentation will take place on Tuesday, October 25, 2005 at 9:40 a.m. Eastern Time at the New York Palace Hotel. A live audio webcast of Mr. Weiss’ presentation will be available at http://www.wsw.com/webcast/ceut3/kerx/. An archived version of the webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound for the treatment of diabetic nephropathy, which is currently being tested in a pivotal global Phase 3 and Phase 4 clinical program under an SPA with the FDA. Additionally, Keryx is developing clinical- stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt and other important signal transduction pathways, which is in Phase 2 clinical development. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Keryx Biopharmaceuticals is headquartered in New York City.
Contact: Keryx Biopharmaceuticals, Inc. Ron Bentsur, Vice President, Finance & Investor Relations (212) 531-5965 ron@keryx.com
Keryx Biopharmaceuticals, Inc.
CONTACT: Ron Bentsur, Vice President, Finance & Investor Relations, KeryxBiopharmaceuticals, Inc., +1-212-531-5965, ron@keryx.com
Web site: http://www.keryx.com/
